Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial
Jeffrey Clarke(Duke Medical Center), Edward F. Patz(G1 Therapeutics (United States)), Stephen J. Balevic(Duke University), James E. Herndon(Duke University), Thomas E. Stinchcombe(Duke Medical Center), Lin Gu(Tsinghua University), You‐Wen He(Duke University), Hirva Mamdani(Wayne State University), Huihua Li(Dalian Medical University), Andrew B. Nixon(Duke University), Scott Antonia(Parker Institute for Cancer Immunotherapy), Ruchi Saxena(Central Drug Research Institute), Guru Sonpavde(AdventHealth Orlando), Michael J. Campa(Duke University), Neal Ready(Duke University), Elizabeth B. Gottlin(Duke University), George R. Simon(Ohio Department of Health), Jeffrey Crawford(Duke University)
Cited by 17
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Exploring atomic defects in molybdenum disulphide monolayers
|Nature Communications|2015|1.5k
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
|The Lancet Oncology|2016|1.3k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
Matching the kinetics of natural enzymes with a single-atom iron nanozyme
|Nature Catalysis|2021|1.1k